Employing our mouse models differentially expressing GFI1, we were thus interested in evaluating the therapeutic potential of curcumin in a setting of MDS-AML patients expressing reduced GFI1 or GFI1-36N SNP variant. The gene discussed is GFI1; the disease is acute myeloid leukemia.